Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine-docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population.

In 30 seconds

This prospective, randomized, parallel-arm study compared intravesical gemcitabine-docetaxel (Gem/Doce) with BCG as adjuvant treatment for BCG-naïve intermediate- or high-risk non-muscle-invasive bladder cancer in Indian patients after complete TURBT. Among 91 patients, 12-month recurrence-free survival (RFS) was 90.71% with Gem/Doce and 77.08% with BCG. Adverse events were reported by 13.95% and 35.42%, respectively; no Grade ≥3 events occurred with Gem/Doce, compared with three in the BCG group. The authors report higher intermediate-risk RFS with Gem/Doce and comparable survival outcomes.

Key findings

• At 12 months, RFS was 90.71% with Gem/Doce versus 77.08% with BCG.
• For intermediate-risk disease, 12-month RFS was 93.55% versus 81.82% (p = 0.041) with Gem/Doce and BCG, respectively.
• Adverse events occurred in 13.95% with Gem/Doce and 35.42% with BCG; there were no Grade ≥ 3 events with Gem/Doce versus three with BCG.
• At 12 months, progression-free survival was 97.67% versus 95.83%, cancer-specific survival 100% versus 97.92%, and overall survival 100% versus 95.83% with Gem/Doce and BCG, respectively.

Why it matters

BCG is an established adjuvant option for intermediate- and high-risk NMIBC, but treatment failure, toxicity, and supply constraints are concerns noted by the authors. This randomized comparison suggests sequential Gem/Doce may offer a less toxic alternative while maintaining encouraging short-term disease-control and survival outcomes. The findings are relevant to evaluating intravesical options, but do not establish long-term comparative effectiveness.

What to keep in mind

Follow-up outcomes were reported only through 12 months, and the authors state that larger multicentre studies are needed for long-term validation.